TORONTO, Feb. 27,
2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the
"Company") (TSX: HLS), announces that it will release its Q4 and
fiscal 2024 financial results on Thursday,
March 13, 2025. The Company will hold a conference call that
same day at 8:30 a.m. ET to discuss
its results. The call will be hosted by Craig Millian, Chief Executive Officer;
John Hanna, Chief Financial Officer;
and Brian Walsh, Chief Commercial
Officer. Slides to accompany management's prepared remarks will
be available to view via the webcast.
CONFERENCE ID: 29035
DATE: Thursday, March 13, 2025
TIME: 8:30 a.m. ET
WEBCAST
LINK: https://app.webinar.net/rZxdqA40KDB
TRADITIONAL DIAL-IN NUMBER: 1-888-699-1199 or
1-416-945-7677
RAPIDCONNECT: To instantly join the conference call
by phone, please use the following URL to easily register and be
connected into the conference call automatically:
https://emportal.ink/4fZYDLM
TAPED REPLAY: 1-888-660-6345 or 1-646-517-4150
REPLAY CODE: 29035#
The taped replay will be available for 14 days and the archived
webcast will be available for 365 days.
A link to the live audio webcast of the conference call will
also be available on the events page of the investors section of
HLS Therapeutics' website at www.hlstherapeutics.com. Please
connect at least 15 minutes prior to the conference call to ensure
adequate time for any software download that may be required to
hear the webcast.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a
pharmaceutical company focused on the acquisition and
commercialization of late-stage development, commercial stage
promoted and established branded pharmaceutical products in the
North American markets. HLS's focus is on products that address
unmet needs in the treatment of psychiatric disorders and
cardiovascular disease. HLS's management team is composed of
seasoned pharmaceutical executives with a strong track record of
success in these therapeutic areas and at managing products in each
of these lifecycle stages. For more information visit:
www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.
